CHA Vaccine Institute’s Lipo-pam added to CEPI’s pandemic adjuvant library

CHA Vaccine Institute said Wednesday its proprietary adjuvant Lipo-pam has been added to the Coalition for Epidemic Preparedness Innovations’ (CEPI) Adjuvant Library, making it the only Korean company among 14 global organizations selected alongside groups from the U.S., the U.K., and Japan.

CEPI, a public-private partnership launched at Davos in 2017, funds and coordinates vaccine R&D against emerging infectious diseases. Its Adjuvant Library, overseen by the U.K. Medicines and Healthcare products Regulatory Agency, is part of the “100 Days Mission” to accelerate vaccine development in future pandemics. 

Candidates were chosen based on development stage, diversity, scalability and feasibility of supply to low- and middle-income countries, according to CHA Vaccine Institute’s release.

Inclusion gives the company a chance to supply Lipo-pam to CEPI-backed developers, who will test it in preclinical vaccine-adjuvant combinations to help determine clinical potential. CHA Vaccine Institute said the recognition positions it as a strategic partner in the global vaccine ecosystem and could expand opportunities for collaborations with vaccine makers.

“Adjuvants have been critical to enhancing vaccine efficacy for more than a century. Yet during Covid-19, shortages meant developers had to rely on available combinations rather than optimal ones,” CEPI CEO Richard Hatchett said. “The Adjuvant Library will enable faster, more effective pairing of vaccines and adjuvants, significantly accelerating future pandemic responses.”